Flu Vaccine Candidate Elicits Enhanced Immune Response

JAMA ◽  
2021 ◽  
Vol 326 (18) ◽  
pp. 1784
Author(s):  
Jennifer Abbasi
Keyword(s):  
Immune Response ◽  
Vaccine Candidate ◽  
Flu Vaccine

Effects of feeding Isomaltooligosaccharides on the growth performance, carcass traits and immune response of broiler chickens

2014 ◽  
Vol 3 (1) ◽  
pp. 150-157
Author(s):  
Khalid M. Gaafar
Keyword(s):  
Immune Response ◽  
Growth Performance ◽  
Broiler Chickens ◽  
Carcass Traits ◽  
Dietary Supplementation ◽  
Control Group ◽  
Broiler Chicks ◽  
Feed Conversion ◽  
Flu Vaccine ◽  
Lipids Profile

The research was conducted to study the effect of feeding broiler chickens on diets containing isomaltooligosaccharides on the growth performance, carcass traits and immune response. 90-one day old broiler chicks were used according to completely randomized two treatment groups and one control, 30 birds each. Birds fed ad-libitum on basal starter and grower-finisher diets for 35 day. Diets of treatment`s groups contained 0.5 g/Kg and 1 g/Kg of Isomaltooligosaccharides, while the control group fed on the basal diets without Isomaltooligosaccharides supplementation. Dietary supplementation of broiler chickens with Isomaltooligosaccharides improved body weight, feed conversion, carcass traits, two lymphoid organs weight and log antibody titer against avian flu vaccine. Most of the highest values were for birds fed low levels of Isomaltooligosaccharides. Feed intake decreases as Isomaltooligosaccharides level increases. Dietary supplementation with Isomaltooligosaccharides did not affect the lipids profile (triglycerides, total cholesterol, LDL and HDL), however the blood VLDL levels decreased with increased levels of Malondialdehyde and Glutathione reductase. Collectively, Dietary supplementation of broiler chickens with 0.5 g/Kg diet of Isomaltooligosaccharides improved growth performance, carcass traits and immune status.

Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2

Vaccine ◽  
2021 ◽  
Author(s):  
Sreedam C. Das ◽  
Jason D. Price ◽  
Katharine Gosling ◽  
Nicola MacLennan ◽  
Ricardo Ataíde ◽  
...  
Keyword(s):  
Immune Response ◽  
Malaria Vaccine ◽  
Vaccine Candidate ◽  
Malaria Vaccine Candidate

scholarly journals Simultaneous Immunization with Multivalent Norovirus VLPs Induces Better Protective Immune Responses to Norovirus than Sequential Immunization

Viruses ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1018
Author(s):  
Maria Malm ◽  
Timo Vesikari ◽  
Vesna Blazevic
Keyword(s):  
Immune Response ◽  
Immune Responses ◽  
Antibody Response ◽  
Vaccine Candidate ◽  
Serum Antibodies ◽  
Blocking Antibody ◽  
Alternative Approach ◽  
Sequential Boost ◽  
Trivalent Vaccine ◽  
Rotavirus Vp6

Human noroviruses (NoVs) are a genetically diverse, constantly evolving group of viruses. Here, we studied the effect of NoV pre-existing immunity on the success of NoV vaccinations with genetically close and distant genotypes. A sequential immunization as an alternative approach to multivalent NoV virus-like particles (VLPs) vaccine was investigated. Mice were immunized with NoV GI.3, GII.4-1999, GII.17, and GII.4 Sydney as monovalent VLPs or as a single tetravalent mixture combined with rotavirus VP6-protein. Sequentially immunized mice were primed with a trivalent vaccine candidate (GI.3 + GII.4-1999 + VP6) and boosted, first with GII.17 and then with GII.4 Sydney VLPs. NoV serum antibodies were analyzed. Similar NoV genotype-specific immune responses were induced with the monovalent and multivalent mixture immunizations, and no immunological interference was observed. Multivalent immunization with simultaneous mix was found to be superior to sequential immunization, as sequential boost induced strong blocking antibody response against the distant genotype (GII.17), but not against GII.4 Sydney, closely related to GII.4-1999, contained in the priming vaccine. Genetically close antigens may interfere with the immune response generation and thereby immune responses may be differently formed depending on the degree of NoV VLP genotype identity.

FLU-v, a Universal Flu Vaccine Candidate, Advances in Trial

JAMA ◽  
2020 ◽  
Vol 323 (14) ◽  
pp. 1336
Author(s):  
Jennifer Abbasi
Keyword(s):  
Vaccine Candidate ◽  
Flu Vaccine

scholarly journals Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C

PLoS ONE ◽  
2012 ◽  
Vol 7 (4) ◽  
pp. e35485 ◽  
Author(s):  
Carmen Elena Gómez ◽  
Beatriz Perdiguero ◽  
Victoria Jiménez ◽  
Abdelali Filali-Mouhim ◽  
Khader Ghneim ◽  
...  
Keyword(s):  
Immune Response ◽  
Systems Analysis ◽  
Vaccine Candidate ◽  
Clade C ◽  
Hiv Aids

scholarly journals A Vaccine Displaying a Trimeric Influenza-A HA Stem Protein on Capsid-Like Particles Elicits Potent and Long-Lasting Protection in Mice

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 389
Author(s):  
Susan Thrane ◽  
Kara-Lee Aves ◽  
Ida E. M Uddbäck ◽  
Christoph M. Janitzek ◽  
Julianna Han ◽  
...  
Keyword(s):  
Immune Response ◽  
Single Dose ◽  
Pandemic Influenza ◽  
Influenza A ◽  
H1n1 Influenza ◽  
Antigenic Drift ◽  
Promising Target ◽  
Flu Vaccine ◽  
Neutralizing Epitopes

Due to constant antigenic drift and shift, current influenza-A vaccines need to be redesigned and administered annually. A universal flu vaccine (UFV) that provides long-lasting protection against both seasonal and emerging pandemic influenza strains is thus urgently needed. The hemagglutinin (HA) stem antigen is a promising target for such a vaccine as it contains neutralizing epitopes, known to induce cross-protective IgG responses against a wide variety of influenza subtypes. In this study, we describe the development of a UFV candidate consisting of a HAstem trimer displayed on the surface of rigid capsid-like particles (CLP). Compared to soluble unconjugated HAstem trimer, the CLP-HAstem particles induced a more potent, long-lasting immune response and were able to protect mice against both homologous and heterologous H1N1 influenza challenge, even after a single dose.

scholarly journals Plasmodium vivax recombinant vaccine candidate AMA-1 plays an important role in adaptive immune response eliciting differentiation of dendritic cells

Vaccine ◽  
2009 ◽  
Vol 27 (41) ◽  
pp. 5581-5588 ◽  
Author(s):  
Lilian Lacerda Bueno ◽  
Cristiane Guimarães Morais ◽  
Irene da Silva Soares ◽  
Leoneide Erica Maduro Bouillet ◽  
Oscar Bruna-Romero ◽  
...  
Keyword(s):  
Immune Response ◽  
Dendritic Cells ◽  
Plasmodium Vivax ◽  
Vaccine Candidate ◽  
Adaptive Immune Response ◽  
Recombinant Vaccine ◽  
Adaptive Immune

scholarly journals Recombinant Holotoxoid Vaccine against Botulism

2007 ◽  
Vol 76 (1) ◽  
pp. 437-442 ◽  
Author(s):  
Christina L. Pier ◽  
William H. Tepp ◽  
Marite Bradshaw ◽  
Eric A. Johnson ◽  
Joseph T. Barbieri ◽  
...  
Keyword(s):  
Immune Response ◽  
Heavy Chain ◽  
Cortical Neurons ◽  
Clostridium Botulinum ◽  
Vaccine Candidate ◽  
Primary Cortical Neurons ◽  
Current Vaccine ◽  
Botulinum Neurotoxins ◽  
Double Amino Acid ◽  
Limited Supply

ABSTRACT The botulinum neurotoxins (BoNT) are the most toxic proteins for humans and designated “Category A Select Agents.” The current vaccine against botulism is in limited supply, and there is a need to develop new vaccine strategies. A recombinant BoNT/A toxoid was produced in Clostridium botulinum that contained a double amino acid substitution, R363A Y365F (termed BoNT/ARYM). BoNT/ARYM was noncatalytic for SNAP25 and nontoxic for mice. Immunization with BoNT/ARYM protected mice from challenge at levels that were similar to chemically inactivated BoNT/A toxoid. BoNT/ARYM elicited an immune response against the light-chain and heavy-chain components of the toxin. Neutralizing anti-BoNT/ARYM sera blocked BoNT toxicity in primary cortical neurons and blocked ganglioside binding by the heavy chain. BoNT/ARYM represents a viable vaccine candidate for a holotoxoid against botulism.

Sign in / Sign up

Export Citation Format

Share Document